Clinical Trial Update: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial investigates a dual-targeting CD19-CD22 CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia. The study, s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19/CD22 CAR-T cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | Status: TERMINATED